Drug intelligence / Profile preview

VUM02

Development stage: Phase 2
Lead developer: Vcanbiopharma
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

VUM02 is an allogeneic cell therapy product comprising culture-expanded mesenchymal stem cells derived from human umbilical cord tissue. It is cryopreserved with a cell concentration of 5 x 10^6 cells/mL. The product is being developed for multiple indications including idiopathic pulmonary fibrosis (IPF) and steroid-refractory acute graft-versus-host disease (SR-aGvHD). As a mesenchymal stem cell therapy, it likely functions through immunomodulatory and anti-inflammatory mechanisms.

Brand names: VUM02 InjectionVUM-02 InjectionVUM 02 Injection
Other names: Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells InjectionhUCT-MSChuman umbilical cord-derived mesenchymal stromal/stem cells

Beyond the preview

Go deeper on VUM02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VUM02.

Explore the full profile